

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 1/14, 1/18, 1/20, 1/30, 1/34, 1/36, 14/505	A1	(11) International Publication Number: WO 00/27869 (43) International Publication Date: 18 May 2000 (18.05.00)
(21) International Application Number: PCT/US99/26241 (22) International Filing Date: 8 November 1999 (08.11.99) (30) Priority Data: P98 01 05610 6 November 1998 (06.11.98) AR P99 01 00680 23 February 1999 (23.02.99) AR (71) Applicant (for all designated States except US): STERREN-BELD BIOTECHNOLOGIE NORTH AMERICA, INC. [US/US]; 1209 Orange Street, Wilmington, DE 19801 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): CARCAGNO, Carlos, Miguel [AR/AR]; Guevara 275, 1427 Buenos Aires (AR). CRISCUOLO, Marcelo [AR/AR]; Guevara 349, Capital Federal (AR). MELO, Carlos [AR/AR]; Alsina 2737, Del Viso, Pcia, Buenos Aires (AR). VIDAL, Juan, Alejandro [AR/AR]; 9th floor, Apartment A, Guise 1760, 1425 Buenos Aires (AR). (74) Agents: GOLDSTEIN, Jorge, A. et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., Suite 600, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHODS OF PURIFYING RECOMBINANT HUMAN ERYTHROPOIETIN FROM CELL CULTURE SUPERNATANTS (57) Abstract <p>The present invention relates, in general, to a method of purifying recombinant human erythropoietin (EPO). The present invention also relates to a substantially pure EPO. The method comprises a differential precipitation, an hydrophobic interaction chromatography, various concentration and diafiltration steps, tandem anionic and cationic exchange chromatographies and molecular exclusion chromatography for the obtaining of pure EPO. The method does not comprise high performance liquid chromatography steps. The invention also comprises the EPO obtained according to the claimed procedure.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Methods of Purifying Recombinant Human Erythropoietin from Cell Culture Supernatants

5 *Background of the Invention*

Field of the Invention

Methods to obtain recombinant human erythropoietin (EPO) characterized
10 by a sequence of tandem separation steps that includes differential precipitation,
hydrophobic interaction, anionic exchange, cationic exchange and molecular
exclusion liquid chromatographies. The EPO obtained by using the methods thus
described.

15 *Background Information*

EPO is a glycoprotein that stimulates erythroblast differentiation in the
bone marrow, thus increasing the circulating blood erythrocyte count. The mean
life of erythrocytes in humans is 120 days and therefore, a human being losses
20 1/120 erythrocytes each day. This loss must be continuously restored to maintain
a stable level of red blood cells.

The existence of EPO was first postulated by the turn of the century and
was definitely proved by Reissman and Erslev early in the '50s. See Carnot, et al.,
C.R. Acad. Sci. (France), 143, 384-6 (1906); Carnot, et al., *C.R. Acad. Sci.*
25 *(France)*, 143, 432-5 (1906); Carnot, et al., *C.R. Soc. Biol.*, 111, 344-6 (1906);
Carnot, *C.R. Soc. Biol.*, 111, 463-5 (1906); Reissman, *Blood*, 1950, 5, 372-80
(1950) and Erslev, *Blood*, 8, 349-57 (1953). Reissman and Erslev's experiments
were promptly confirmed by other researchers. See Hodgson, et al., *Blood*, 9,
299-309 (1954); Gordon, et al., *Proc. Soc. Exp. Biol. Med.*, 86, 255-8 (1954) and
30 Borsook, et al., *Blood*, 9, 734-42 (1954).

The identification of the EPO production site in the organism was an issue
of debate. Successive experiments led to identify the kidney as the main organ
and peritubular interstitial cells as the synthesis site. See Jacobson, et al., *Nature*,
179, 633-4 (1957); Kuratowska, et al., *Blood*, 18, 527-34 (1961); Fisher, *Acta*
35 *Hematol.*, 26, 224-32 (1961); Fisher, et al., *Nature*, 205, 611-2 (1965); Frenkel,

et al., *Ann. N.Y. Acad. Sci.*, 149, 1, 292-3 (1968); Busuttil, et al., *Proc. Soc. Exp. Biol. Med.*, 137, 1, 327-30 (1971); Busuttil, *Acta Haematol.*, (Switzerland), 47, 4, 238-42 (1972); Erslev, *Blood*, 44, 1, 77-85 (1974); Kazal, *Ann. Clin. Lab. Sci.*, 5, 2, 98-109 (1975); Sherwood, et al., *Endocrinology*, 99, 2, 504-10 (1976);
5 Fisher, *Ann. Rev. Pharmacol. Toxicol.*, 28, 101-22 (1988); Jelkmann, et al., *Exp. Hematol.*, 11, 7, 581-8 (1983); Kurtz, et al., *Proc. Natl. Acad. Sci. (USA)*, 80, 13, 4008-11 (1983); Caro, et al., *J. Lab. Clin. Med.*, 103, 6, 922-31 (1984); Caro, et al., *Exp. Hematol.*, 12, 357 (1984); Schuster, et al., *Blood*, 70, 1, 316-8 (1986); Bondurant, et al., *Mol. Cell. Biol.*, 6, 7, 2731-3 (1986); Bondurant, et al., *Mol.*
10 *Cell. Biol.*, 6, 7, 2731-3 (1986); Schuster, et al., *Blood*, 71, 2, 524-7 (1988); Koury, et al., *Blood*, 71, 2, 524-7 (1988); Lacombe, et al., *J. Clin. Invest.*, 81, 2, 620-3 (1988); Koury, et al., *Blood*, 74, 2, 645-51 (1989).

A smaller proportion, ranging from 10% to 15% of total EPO, is produced by the liver in adults. See Naughton, et al., *J. Surg. Oncol.*, 12, 3, 227-42 (1979);
15 Liu, et al., *J. Surg. Oncol.*, 15, 2, 121-32 (1980); Dornfest, et al., *Ann. Clin. Lab. Sci.*, 11, 1, 37-46 (1981); Dinkelaar, et al., *Exp. Hematol.*, 9, 7, 796-803 (1981); Caro, et al., *Am. J. Physiol.*, 244, 5 (1983); Dornfest, et al., *J. Lab. Clin. Med.*, 102, 2, 274-85 (1983); Naughton, et al., *Ann. Clin. Lab. Sci.*, 13, 5, 432-8 (1983); Jacobs, et al., *Nature*, 313, 6005, 806-10 (1985); Erslev, et al., *Med. Oncol.*
20 *Tumor. Pharmacother.*, 3, 3-4, 159-64 (1986). The EPO produced is directly proportional to the extent of tissular hypoxia and its expression rises by increasing the number of the EPO producing cells.

EPO has shown great efficiency in the treatment of anemia, especially anemia derived from renal failure. See Eschbach, et al., *N. England J. of Med.*,
25 316, 2, 73-78 (1987); Krane, *Henry Ford Hosp. Med. J.*, 31, 3, 177-181 (1983). Its therapeutical usefulness, however, has been limited due to the unavailability of a massive production method. The quantity and quality of the EPO obtained by the extractive systems known were insufficient. Recently, the use of recombinant DNA technology has made it possible to obtain large amounts of
30 proteins. The application of these techniques to eukaryotic cells has allowed a large scale production of EPO. See patents US 5,688,679 (to Powell), US 5,547,933 (to Lin), US 5,756,349 (to Lin), US 4,703,008 (to Lin) and US 4,677,195 (to Hewick et al.).

Several techniques for the separation of glycoproteins such as EPO are currently available. Ultrafiltration, column electrofocusing, flat-bed electrofocusing, gel filtration, electrophoresis and isotachophoresis and some others chromatographic methods have been utilized for the purification of glycoproteins. The most widely used chromatographic techniques have been ionic exchange chromatography and adsorption chromatography.

The ionic exchange method is a separation technique by which the components of a solution are distinguished according to their different net charges and isolated by elution, either in stages or through the application of a continual gradient, with eluents of different ionic strength or pH. This method employs a gel or resin matrix, either of positive or negative charge, to induce binding or electrostatic adsorption of components with opposite charges. During desorption or elution, sample components are exchanged by ions present in the solution or buffer used to elute, or by a change in pH that alters the net charge of the molecule of interest.

Reverse phase adsorption chromatography involves separating the sample components according to their different polarities. Sample components are adsorbed through a resin composed of a silica matrix covered with an organic polymer by non-covalent bonding. The selective desorption of the components occurs afterwards by the elution with a non-polar solvent containing the eluent.

The separation techniques described above were utilized initially to separate relatively small hydrophobic or hydrophilic molecules. Their application to the purification of larger molecules, such as proteins, and specially complex proteins such as lipoproteins, nucleoproteins and glycoproteins, is more recent. Numerous publications illustrate the state of the art attained so far in protein separation.

See Soferet et al., "Handbook of Process Chromatography" (Academic Press Inc., San Diego, California, 1997); Olson, Ed., "Separation Technology" (Interpharm Press, Inc., Buffalo Grove, Illinois, 1995); Franks, Ed., "Protein Biotechnology" (Human Press, Totowa, New Jersey, 1993); Deutscher, Ed., "Guide to Protein Purification, Methods in Enzymology", Vol. 182, (Academic Press Inc., San Diego, California, 1991); Seetharam et al., Eds., "Purification and Analysis of Recombinant Proteins" (Marcel Dekker, Inc., New York, New York,

1991); Harria et al., Eds., "Protein Purification Applications" (Oxford University Press, Oxford, England, 1990); Brown, et al., *Analytical Biochemistry*, 99, 1-21, 1979; Harrison et al., "VDYAC TM Comprehensive Guide to Reverse Phase Materials for HPLC", pp. 1-12 (The Sep/A/Ra/Tions Groups, Hesperia, California, 1984). The use of monoclonal antibodies raised against the protein of interest is another known method of protein recovery.

Several specific methods for recombinant EPO separation have been recently reported. One of these methods consists in protein purification by anionic exchange chromatography with selective protease elimination, followed by reverse phase chromatography and filtration. See US patent 4,667,016 (to Lai et al.). This technique claims a yield of 16% EPO of unknown specific activity and purity.

Another method proposed for the separation of recombinant EPO consists in the application of reverse phase high pressure liquid chromatography (RP-HPLC) to a solution containing partially purified protein. See US patent 4,667,195 (to Hewick et al.). This method has been found irreproducible in practice. Moreover, the non-polar solvents commonly employed or recommended for protein and polypeptide separation by means of RP-HPLC, include reagents such as acetonitrile, difficult to remove from the protein of interest and potentially toxic for human beings. See Parsons, et al., *Endocrinology*, 114, 6, 2223-7 (1984). It should be noted, however, that ethanol and formic acid aqueous solutions for protein elution have also been used. See Takagaki, et al., *Journal of Biological Chemistry*, 5, 4, 1536-41 (1980).

Even though there is abundant information regarding the production of recombinant human EPO, a purification method yielding EPO adequate for its utilization in human beings has not yet been described. A suitable protein purification method should yield EPO over 99% pure and free of contaminants such as: aggregated material, b) degraded material, c) spurious proteins and d) proteases. A protein purity under 99% or the presence of any of the above mentioned contaminants might be toxic for human beings.

On the other hand, many of the methods proposed for EPO purification are not efficient when applied to industrial scale protein production. The RP-HPLC method employs expensive organic solvents, which increases

purification costs. In addition, organic solvents are more difficult to handle and contaminant to the environment. Other purification methods proposed are irreproducible in practice or have a low yield.

Summary of the Invention

The novel method of the present invention describes, in detail, a system for EPO purification whereby a high recovery of a product of high purity and quality is achieved. This product may be used without further purification to formulate pharmaceutical compounds as injectable products for use in human medicine.

An advantage of the claimed invention is the attainment of EPO protease free without any undesirable molecular variants such as aggregates, degraded material or molecules of unexpected isoelectric point values. The EPO obtained by the claimed invention is over 99% pure and could be utilized to prepare pharmaceutical formulations adequate for administration to human beings without any additional purification step. The EPO obtained by the claimed invention is a micro-heterogeneous protein comprising between five to eight isoforms with isoelectric points ranging between 3.0 and 4.5 and *in vivo* specific biological activity over 100,000 IU/mg protein measured by a ⁵⁹Fe incorporation ex-hypoxic polycythemic mice assay and an EPO total mass spectrophotometric assay at 280 nm.

An additional advantage of the claimed invention is its low environmental impact. The method claimed is a clean process that does not employ separation steps based on RP-HPLC technology, thus avoiding the use of organic solvents that may be harmful to the environment.

Yet another advantage of the claimed invention is the non-exposure of EPO to stringent temperature conditions, harmful organic solvents or other solutions that may affect its biological activity or result in a toxic compound unsuitable for human use.

The following detailed description and examples illustrate the separation steps performed in the claimed method.

Brief Description of the Figures

5 **Figure 1** illustrates polyacrylamide gel (SDS-PAGE) analysis of an EPO sample obtained following the method described after purification. In lanes 1, 4 and 7, molecular weight markers were loaded. In lanes 2, 3, 5 and 6, different amounts of pure EPO obtained according to the claimed procedure were run. The purity of the product obtained and the apparent molecular weight exceeding 34 kDa is coincident with the one reported for urinary human EPO as could be clearly observed.

10 **Figure 2** illustrates a Western blot analysis of an EPO sample obtained according to the method described. Identity of the EPO produced is assessed, since it is recognized by a monoclonal antibody against human EPO. In lanes 1 and 2, a human EPO standard and molecular weight markers were loaded, respectively. EPO samples obtained according to the claimed method were loaded in lanes 3 to 5.

15 **Figure 3** shows a SDS-PAGE analysis of a pure EPO sample obtained according to the method described, treated with glycanases. Molecular weight markers were loaded in lanes 1, 4 and 8. Lanes 2 and 7 correspond to untreated EPO. In lane 3, O-glycanase treated EPO was loaded; the presence of an O-glycosylation site is verified. In lane 5, N-glycanase partially digested EPO was loaded. The presence of 3 N-glycosylated molecules with molecular weights as expected for EPO can be verified. Lane 6 was loaded with EPO digested with N-glycanase, and the expected molecular weight for the wholly deglycosylated protein was obtained.

25 **Figure 4** illustrates a survey of the isoelectric points in pure EPO samples produced according to the method described. EPO samples were run in lanes 2, 3 and 4, isoelectric point markers in lanes 1 and 5. The presence of isoforms corresponding to EPO are verified, showing an isoelectric point range of 3.0 to 4.5.

30 **Figure 5** shows the purity of an EPO sample produced according to the method herein described using a reverse phase high performance liquid chromatography.

Figure 6 illustrate the purity of an EPO sample produced according to the method herein described using a molecular exclusion high performance liquid chromatography.

5

Detailed Description of the Invention

The present invention relates to a method of purifying EPO which comprises treating cell culture supernatants comprising EPO by a combination of the following steps: differential precipitation, hydrophobic interaction chromatography, diafiltration, anionic exchange chromatography, cationic exchange chromatography and molecular exclusion chromatography.

Preferred EPO producing recombinant cells comprise a vector which comprises a nucleotide sequence encoding the EPO polypeptide consisting of the amino acid sequence in SEQ ID NO:1, a viral promoter and a viral terminator. Preferred cells contain vectors which confer resistance to both methotrexate and neomycin-derived antibiotics. Preferably, the EPO nucleic acid molecule comprises the nucleic acid molecule described in Lin, "DNA Sequences Encoding Erythropoietin," U.S. Patent No. 4,703,008. Preferably, the viral promoter is an SV40 early promoter.

A preferred method of obtaining EPO from recombinant cells is culturing in media comprising insulin. Specifically, such culturing comprises separating the supernatant which comprises EPO and insulin from the host cells of the invention, concentrating the supernatant and freezing the concentrated product. Preferably, the culture media comprises between 0.5 mg and 20 mg insulin per liter of culture media.

The invention further relates to a method of purifying EPO which comprises treating cell culture supernatants comprising EPO by the following steps in order: (a) differential precipitation, (b) hydrophobic interaction chromatography, (c) diafiltration, (d) anionic exchange chromatography, (e) cationic exchange chromatography and (f) molecular exclusion chromatography. The present invention relates to a method of purifying EPO which comprises treating cell culture supernatants comprising EPO by a combination of the

following steps: differential precipitation, hydrophobic interaction chromatography, 2 diafiltration steps, anionic exchange chromatography, cationic exchange chromatography and molecular exclusion chromatography.

5 The invention further relates to a method of purifying EPO which comprises treating cell culture supernatants comprising EPO by a following steps in order: (a) differential precipitation, (b) hydrophobic interaction chromatography, (c) diafiltration, (d) anionic exchange chromatography, (e) cationic exchange chromatography, (e') diafiltration and (f) molecular exclusion chromatography.

10 The differential precipitation step of the above and below-described methods and compositions comprises adding ammonium sulfate to said supernatant, followed by centrifugation.

The hydrophobic interaction chromatography step of the above and below-described methods and compositions comprises using an hydrophobic interaction matrix. Preferably said interaction matrix is Phenyl Sepharose 6 Fast Flow.

15 The anion exchange step of the above and below-described methods and compositions comprises using an anion exchange matrix. Preferably said anion exchange matrix comprises Q-Sepharose Fast Flow.

20 The cation exchange step of the above and below-described methods and compositions comprises using a cation exchange matrix. Preferably said cation exchange matrix comprises SP-Sepharose Fast Flow.

25 The molecular exclusion step of the above and below-described methods and compositions comprises using a molecular exclusion matrix. Preferably said molecular exclusion matrix is Sephacryl S-200 HP.

30 In another embodiment, the present invention provides a substantially pure EPO. Preferably, said EPO is produced by a combination of the following steps: differential precipitation, hydrophobic interaction chromatography, diafiltration, anionic exchange chromatography, cationic exchange chromatography and molecular exclusion chromatography. More preferably, said EPO has a purity of greater than 99% as determined by SDS-PAGE gel electrophoresis.

A preferred method of using the purified EPO of the present invention comprises lyophilization into a form suitable for injection into humans for

treatment of disease. Specifically, the preferred lyophilization procedure comprises placing the EPO into a pharmaceutical composition, loading the first EPO composition into a container, wherein said container is at a temperature equal to or less than -30°C ; incubating said EPO composition at a temperature equal to or less than -30°C under atmospheric pressure for a time equal to or greater than 4 hours; incubating said composition at a pressure of equal to or less than 30 absolute microns for a time equal to or greater than one hour; and raising the temperature equal to or less than 3°C per hour until reaching at least 25°C , while keeping pressure values equal to or less than 5 absolute microns.

A preferred pharmaceutical composition for lyophilization comprises EPO, sugar, salts and human albumin. An especially preferred composition for lyophilization comprises EPO, mannitol, NaCl, NaH_2PO_4 and $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$.

The present invention is described in further detail in the following non-limiting examples.

Examples

Example 1 Recovery

7,920 g of ammonium sulfate were dissolved in 30 liters of sterile concentrated solution obtained from culturing CHO (Chinese Hamster Ovary) cells producing EPO. After addition of ammonium sulfate, the solution was stored at 4°C for 24 hours. Many contaminant proteins precipitated while the EPO remained in solution. The product was centrifuged at 5,000 RPM for 10 minutes in a Sorvall centrifuge, using a HG4L rotor.

Example 2 Hydrophobic Interaction Chromatography

The material obtained from the previous step is chromatographed using an Hydrophobic Interaction matrix (Phenyl Sepharose 6 Fast Flow low sub.-Pharmacia) according to the following parameters:

1. Equipment:

-10-

A. Pre-column:

- 1) Diameter: 14 cm
- 2) Bed height: 19 cm
- 3) Matrix:
 - a) Q-Sepharose Big Bead (Pharmacia)
 - b) Volume: 3,000 ml

B. Column:

- 1) Diameter: 20 cm
- 2) Bed height: 19 cm
- 3) Matrix:
 - a) Phenyl-Sepharose 6 Fast Flow low sub.
(Pharmacia)
 - b) Volume: 6,000 ml

2. Solutions and buffers:

- A. Buffer A: 10mM NaH_2PO_4 , pH 7.2
- B. Buffer F: 10mM NaH_2PO_4 , 1.8 M $(\text{NH}_4)_2\text{SO}_4$, pH 7.2
- C. Buffer G: 150mM NaH_2PO_4 , pH 7.2
- D. 20% isopropyl alcohol
- E. 0.5 N NaOH

3. Material to be chromatographed:

- A. Ammonium sulfate supernatant resulting from previous example.
- B. Sample conditions:
 - 1) Volume: 30,000 ml
 - 2) Conductivity: 190-210 mSi/cm
 - 3) pH: 7.2

To equilibrate and sanitize the pre-column the following solutions or buffers in the quantities hereinafter detailed were sequentially passed through it: 1.0 volume of the column ("vc") (3 l) of H_2O ; 1.0 vc (3 l) of NaOH 0.5N; 1.0 vc (3 l) of Buffer G and finally 1.5 vc (4.5 l) of Buffer F.

-11-

To equilibrate the column the following solutions or buffers in the quantities hereinafter detailed were sequentially passed through it: 1.0 vc (6 l) of H₂O; 1.0 vc (6 l) of 20% isopropyl alcohol; 1.0 vc (6 l) of H₂O; 1.0 vc (6 l) of 0.5 N NaOH; 1.0 vc (6 l) of H₂O; 1.0 vc (6 l) of Buffer G and finally 1.5 cv (9 l) of Buffer F.

Once the pre-column and the column were equilibrated, the column was connected after the pre-column and the material to be chromatographed was loaded. Said loading was performed at 4°C, at a 19 cm/hour flow. Thereafter, the elution was performed at the same flow rate but at room temperature, and the solutions and buffers hereinafter detailed were passed through the columns in the following quantities and order: 2.5 vc (15 l) of Buffer F, (once this buffer has passed through, the pre-column was removed). Once the pre-column was removed, the chromatography was performed on the Phenyl Sepharose column on which a Buffer F-Buffer A gradient was applied starting from a 85:15 ratio of said buffers until 50:50 ratio of said buffers in a total volume of 10 vc (60 l) was reached.

When the gradient was finished, 1.5 vc (9 l) of Buffer F-Buffer A in a 30:70 ratio was passed through the column and finally 1.5 vc (9 l) of H₂O. The selected EPO containing fractions were filtered under sterile conditions through a 0.22 µm pore membrane and stored at 4°C.

Example 3 Concentration and Diafiltration

The fractions resulting from the previous example were concentrated and diafiltered according to the conditions described below:

1. Equipment:

- A. Peristaltic pump: Watson Marlow - Cat. N° 302S
- B. Tubing: Masterflex - Cat. N° 06402-18
- C. Concentrator: Prep Scale Millipore CDU F006LC

2. Solutions and buffers:

- A. 10mM Sodium Dodecyl Sulfate (SDS)

-12-

- B. 1 mM Triton X-100
- C. 0.1N NaOH
- D. H₂O
- E. Buffer A: 10 mM NaH₂PO₄, pH 7.2

5

3. Material to be processed:

- A. Selected fractions resulting from the previous example.
- B. Sample conditions:
 - 1. Volume: 15,000-30,000 ml
 - 2. Conductivity: 130-170 mSi/cm
 - 3. pH: 7.2

10

The equipment was first cleaned, sanitized and equilibrated, and the following sequence of solutions and buffers were flowed through the equipment: 10 l of 10mM SDS; 40 l of H₂O; 10 l of 1 mM Triton X-100, 40 l of H₂O; 10 l of 0.1N NaOH; 40 l of H₂O and finally 5 l of Buffer A. The equipment was then ready to be used for concentration and diafiltration against Buffer A on the selected fractions, following the usual methodology.

15

The final volume of the concentrated product was between 2,000 to 3,000 ml, its conductivity was 1,100-1,550 μ mSi/cm and its pH was 7.2.

20

Example 4 Anionic Exchange Chromatography

The material resulting from the previous example was chromatographed using an anionic exchange matrix, as follows:

25

1. Equipment:

- A. Column:
 - 1) Diameter: 14 cm
 - 2) Bed height: 19 cm
 - 3) Matrix
 - a) Q-Sepharose Fast Flow (Pharmacia)
 - b) Volume: 3,000 ml

30

2. Solutions and buffers:

- A. Buffer A: 10mM NaH₂PO₄, pH 7.2
B. Buffer G: 150 mM NaH₂PO₄, pH 7.2
C. Buffer N: 50mM Acetic Acid, 500 mM NaCl, pH 4.0
D. Buffer S: 50mM Acetic Acid, pH 4.0
E. 0.5 N NaOH

3. Material to be chromatographed

- A. Fractions selected from the hydrophobic interaction step, duly concentrated and diafiltered.
B. Sample conditions:
1) Volume: 2,000 to 3,000 ml
2) Conductivity: 1,100-1,550 μ Si/cm
3) pH: 7.2

To equilibrate the column the following solutions or buffers in the quantities hereinafter detailed were sequentially passed through it: 1.0 vc (3 l) of H₂O; 1.0 vc (3 l) of 0.5 N NaOH; 1.0 vc (3 l) of Buffer N; 2.0 vc (6 l) of Buffer S; 3.0 vc (9 l) of Buffer G; and finally 2.0 vc (6 l) of Buffer A.

Once the column was equilibrated, the material to be chromatographed was loaded. Said loading was performed at room temperature at 39 cm/hour. Thereafter, the elution was performed at the same flow rate and temperature, and the solutions and buffers hereinafter detailed were passed in the following order: 1.0 vc (3 l) of Buffer A and 4.0 vc (12 l) of Buffer S. Thereafter, a Buffer S-Buffer N step (50:50) in a total volume of 1.5 vc (4.5 l) was performed.

Once the step finished, 1.5 vc (4.5 l) of Buffer N was passed through the column. The selected EPO containing fractions, were filtered under sterile conditions through a 0.22 μ m pore membrane and stored at 4°C.

Example 5 Cationic Exchange Chromatography

The material resulting from the previous example was chromatographed using a cationic exchange matrix, as follows:

1. Equipment:

A. Column:

- 1) Diameter: 14 cm
- 2) Bed height: 19 cm
- 3) Matrix
 - a) SP-Sepharose Fast Flow (Pharmacia)
 - b) Volume: 3,000 ml

2. Solutions and buffers

- A. Buffer D: 12.5 mM Na_2HPO_4 , 4mM Citric acid, pH 6.0
- B. Buffer E: 12.5 mM Na_2HPO_4 , 4mM Citric acid, 0.5M NaCl, pH 6.0
- C. 0.5 N NaOH

3. Material to be chromatographed

- A. Fraction selected from the previous example adjusted to pH 6.0 with NaOH cc and diluted until reaching a conductivity of 4,800 $\mu\text{Si}/\text{cm}$ (conductivity equal to Buffer D-Buffer E in a 93.5:6.5 ratio).
- B. Sample conditions:
 - 1) Volume: 5,000 ml
 - 2) Conductivity: 4,800 $\mu\text{Si}/\text{cm}$ (equal to Buffer D-Buffer E in a 93.5:6.5 ratio).
 - 3) pH: 6.0

To equilibrate the column, the following solutions or buffers in the quantities hereinafter detailed were sequentially passed through it: 1.0 vc (3 l) of H_2O ; 1.0 vc (3 l) of 0.5 N NaOH; 1.0 vc (3 l) of Buffer E and finally 1.5 vc (4.5 l) of Buffer D-Buffer E in a 93.5:6.5 ratio.

Once the column was equilibrated, the material to be chromatographed was loaded. Said loading was performed at room temperature at 39 cm/hour. Thereafter, the elution was performed at the same flow rate and temperature, and

the solutions and buffers hereinafter detailed were passed through it in the following order: 1.5 vc (4.5 l) of Buffer D-Buffer E in a 93.5:6.5 ratio. Thereafter, a gradient of Buffer D-Buffer E was applied starting from a 93.5:6.5 ratio of said buffers until a 50:50 ratio of said buffers in a total volume of 2.0 vc (6 l) was reached. Once the gradient was finished, 1.5 vc (4.5 l) of Buffer E was passed through the column. The selected EPO containing fractions were filtered under sterile conditions through a 0.22 μ m pore membrane and stored at 4°C.

Example 6 Concentration and Diafiltration

The fractions resulting from the previous example were concentrated and diafiltered according to the following parameters and conditions:

1. Equipment:

- A. Peristaltic pump: Watson Marlow - Cat. N° 302S
- B. Tubing: Masterflex - Cat. N° 06402-18
- C. Concentrator: Prep Scale Millipore CDU F002LC

2. Solutions and buffers:

- A. 10mM Sodium Dodecyl Sulfate (SDS)
- B. 1 mM Triton X-100
- C. 0.1N NaOH
- D. H₂O
- E. Buffer B: 10 mM NaH₂PO₄, 0.15 M NaCl, 0.05 mg/ml Lactose,
pH 7.2

3. Material to be processed:

- A. Selected fractions resulting from the previous step.
- B. Sample conditions:
 - 1. Volume: 6,000 ml
 - 2. Conductivity: 5,000-8,000 μ Si/cm
 - 3. pH: 6.0

-16-

The equipment was first, cleaned, sanitized and equilibrated, letting pass through it the following sequence of solutions and buffers: 10 l of 10 mM SDS; 40 l of H₂O; 10 l of 1 mM Triton X-100, 40 l of H₂O; 10 l of 0.1N NaOH; 40 l of H₂O and finally 5 l of Buffer B. In this way, the equipment was ready to be used for the concentration and diafiltration procedures against Buffer B on the selected fractions, following the usual methodology.

The final volume of the concentrated product was 350-600 ml, its conductivity was 15,500-19,000 mSi/cm, the pH was 7.2, and the solution was stored at 4°C.

Example 7 Molecular Exclusion Chromatography

The material resulting from the previous example was chromatographed using a molecular exclusion matrix, as follows:

1. Equipment:

A. Column:

- 1) Diameter: 10 cm
- 2) Bed height: 76 cm
- 3) Matrix
 - a) Sephacryl S-200 HP (Pharmacia)
 - b) Volume: 6,000 ml

2. Solutions and buffers:

- A. Buffer B: 10mM NaH₂PO₄, 0.15 M NaCl, 0.05 mg/ml Lactose, pH 7.2
- B. 0.5 N NaOH

3. Material to be chromatographed

- A. Fractions selected from the previous example, concentrated.
- B. Sample conditions:
 1. Volume: 350 to 600 ml
 2. Conductivity: 15,500-19,000 μ Si/cm

3. pH: 7.2

To equilibrate the column the following solutions or buffers in the quantities hereinafter detailed were sequentially passed through it: 1.0 volume of the column ("vc") (6 l) of H₂O; 1.5 vc (9 l) of 0.5 N NaOH and finally 3.0 vc (18 l) of Buffer B. Once the column was equilibrated, 100 ml from the material to be chromatographed were loaded. Said loading was performed at room temperature at 27 cm/hour. Thereafter, the elution was performed at the same flow and temperature rates, and 0.75 vc (4.5 l) of Buffer B was passed through it. This procedure was repeated between four to six times, that is, until the material to be chromatographed was completely utilized. The selected EPO containing fractions were filtered under sterile conditions through a 0.22 μ m pore membrane and stored at 4°C.

With this step the purification process was concluded. The EPO obtained has a purity degree superior to 99% and the entire purification process had a global yield of approximately 30%.

Example 8 EPO Assays

The EPO obtained in the previous example was assayed for identity and biological activity according to the following protocol.

In a denaturing SDS-PAGE gel the EPO was identified as a wide band of molecular weight as expected for EPO. See Figure 1. The band was recognized by monoclonal and polyclonal antibodies raised against human EPO in a Western blot assay as expected for EPO. See Figure 2. The treatment with glycanases proved the existence of the glycosidic chains in the extent and size as expected for EPO. See Figure 3. The EPO produced was shown to be composed of a series of species showing isoelectric points from 3.0 to 4.5 as expected for EPO. See Figure 4.

The complete amino acid sequence of the isolated protein, purified from the culture supernatant of transfected cell lines showed total homology with natural human erythropoietin whose 165 aminoacid sequence is as follows (SEQ ID NO:1):

-18-

	NH ₂ ---	Ala	Pro	Pro	Arg	Leu	Ile	Cys	Asp
		Ser	Arg	Val	Leu	Glu	Arg	Tyr	Leu
		Leu	Glu	Ala	Lys	Glu	Ala	Glu	<u>Asn</u>
		Ile	Thr	Thr	Gly	Cys	Ala	Glu	His
5		Cys	Ser	Leu	Asn	Glu	<u>Asn</u>	Ile	Thr
		Val	Pro	Asp	Thr	Lys	Val	Asn	Phe
		Tyr	Ala	Trp	Lys	Arg	Met	Glu	Val
		Gly	Gln	Gln	Ala	Val	Glu	Val	Trp
		Gln	Gly	Leu	Ala	Leu	Leu	Ser	Glu
10		Ala	Val	Leu	Arg	Gly	Gln	Ala	Leu
		Leu	Val	<u>Asn</u>	Ser	Ser	Gln	Pro	Trp
		Glu	Pro	Leu	Gln	Leu	His	Val	Asp
		Lys	Ala	Val	Ser	Gly	Leu	Arg	Ser
		Leu	Thr	Thr	Leu	Leu	Arg	Ala	Leu
15		Gly	Ala	Gln	Lys	Glu	Ala	Ile	Ser
		Pro	Pro	Asp	Ala	Ala	<u>Ser</u>	Ala	Ala
		Pro	Leu	Arg	Thr	Ile	Thr	Ala	Asp
		Thr	Phe	Arg	Lys	Leu	Phe	Arg	Val
		Tyr	Ser	Asn	Phe	Leu	Arg	Gly	Lys
20		Leu	Lys	Leu	Tyr	Thr	Gly	Glu	Ala
		Cys	Arg	Thr	Gly	Asp	----	COOH	

X glycosilation sites

The presence of the four glycosilation sites on the 165 amino acid chain, as well as the complex carbohydrate structure, and in particular, the sialic acid terminal residues, which characterize EPO were verified. These results were further supported by a biological activity assay of the produced protein by an ex-hypoxic polycythemic mice test, which showed complete concordance with the international EPO standard.

An EPO sample obtained according to the claimed method was submitted to a reverse phase and molecular exclusion high performance liquid chromatography analysis. In both cases, a purity over 99% was proved. See Figures 5 and 6.

-19-

The following table illustrates the recovery of each separation step corresponding to the claimed procedure.

STAGE	RECOVERY (%)
Cell Culture Supernatant	100
Hydrophobic Interaction Chromatography	70
Concentration and Diafiltration I	97
Anionic Exchange Chromatography	82
Cationic Exchange Chromatography	71
Concentration and Diafiltration II	95
Molecular Exclusion Chromatography	79

The following table illustrates the accumulated recovery of the purification sequence claimed in Claim 2.

STAGE	RECOVERY (%)
Cell Culture Supernatant	100
Hydrophobic Interaction Chromatography	70
Concentration and Diafiltration I	68
Anionic Exchange Chromatography	56
Cationic Exchange Chromatography	40
Concentration and Diafiltration II	38
Molecular Exclusion Chromatography	30

* * * * *

All publications mentioned hereinabove are hereby incorporated in their entirety by reference.

While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention and appended claims.

What Is Claimed Is:

1. A method of purifying recombinant human erythropoietin from cell culture supernatants comprising by a combination of the following steps:
 - 5 (a) differential saline precipitation;
 - (b) hydrophobic interaction chromatography;
 - (c) concentration and diafiltration;
 - (d) anionic exchange chromatography;
 - (e) cationic exchange chromatography;
 - 10 (f) concentration and diafiltration;
 - (g) molecular exclusion chromatography.
2. The method of Claim 1, wherein steps a) through g) are performed in the following order: (a), (b), (c), (d), (e), (f) and (g).
- 15 3. The method of Claim 1, wherein steps a) through g) are performed in the following order: (a), (c), (d), (e), (b), (f) and (g).
4. The method of Claim 1, wherein step a) comprises adding ammonium sulfate to said culture supernatant, followed by centrifugation.
- 20 5. The method of Claim 1, wherein step (b) comprises using a hydrophobic interaction matrix.
- 25 6. The method of Claim 5, wherein said hydrophobic interaction matrix employed is Phenyl Sepharose 6 Fast Flow.
7. The method of Claim 1, wherein step (d) comprises using an anionic exchange matrix.
- 30 8. The method of Claim 7, wherein said anionic exchange matrix is Q-Sepharose Fast Flow.

-21-

9. The method of Claim 1, wherein step (e) comprises using a cationic exchange matrix.

10. The method of Claim 9, wherein said cationic exchange matrix is SP-Sephacrose Fast Flow.

11. The method of Claim 1, wherein step (g) comprises using a molecular exclusion matrix.

12. The method of Claim 11, wherein said molecular exclusion matrix employed is Sephacryl S-200 HP.

13. A substantially pure erythropoietin, produced according to the method of Claim 1.

14. The erythropoietin according to Claim 13, wherein said EPO has a purity exceeding 99% as determined by a polyacrilamide gel electrophoresis analysis (SDS-PAGE) and reverse phase and molecular exclusion liquid chromatography.

15. The erythropoietin according to Claim 13, wherein said EPO is characterized by a series of isoforms of isoelectric point values between 3.0 and 4.5.

16. The erythropoietin according to Claim 13, wherein said EPO shows homology to the amino acid sequence of SEQ ID NO:1.

1/3

Fig. 1. Polyacrylamide gel electrophoresis (SDS-PAGE)





Fig. 2. Western blot analysis



2/3

Fig. 3. SDS-PAGE analysis of EPO digestion with glycanases





Fig. 4. Determination of isoelectric point (isoelectric focusing)



3/3

Fig. 5. Reverse phase high performance liquid chromatography





Fig. 6. Molecular exclusion high performance liquid chromatography



-1-

SEQUENCE LISTING

<110> Sterrenbeld Biotechnologie North America, Inc.

Carcagno, Carlos Miguel

Criscuolo, Marcelo

Melo, Carlos

Vidal, Juan Alejandro

<120> Methods of Purifying Recombinant Human Erythropoietin from Cell Culture Supernatants

<130> 1792.003PC02

<140>

<141>

<150> AR 99-01-00680

<151> 1999-02-23

<150> AR 98-01-05610

<151> 1998-11-06

<160> 1

<170> PatentIn Ver. 2.0

<210> 1

<211> 165

<212> PRT

<213> Homo sapiens

<400> 1

Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu

1

5

10

15

Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His

20

25

30

Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe

35

40

45

-2-

Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp
50 55 60

Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu
65 70 75 80

Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp
85 90 95

Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu
100 105 110

Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala
115 120 125


Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val
130 135 140

Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala
145 150 155 160

Cys Arg Thr Gly Asp
165

INTERNATIONAL SEARCH REPORT

 International application No.
 PCT/US99/26241

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C07K 1/14, 1/18, 1/20, 1/30, 1/34, 1/36, 14/505 US CL : 530/380, 412, 414, 416, 417, 418, 419 According to International Patent Classification (IPC) or to both national classification and IPC																										
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 530/380, 412, 414, 416, 417, 418, 419 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE, CAPLUS, EMBASE, SCISearch search terms: erythropoietin, hydropobic chromatography, anion, cation, diafiltration, precipitation																										
C. DOCUMENTS CONSIDERED TO BE RELEVANT																										
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																								
Y - X	US 4,667,016 A(LAI et al) 19 May 1987, see entire document, especially col. 4, lines 4-56.	1-12 ----- 13-16																								
Y - X	Chem. abstr., Vol. 100, No. 25, 18 June 1984 (Columbus, OH, USA), page 77, column 2, the abstract No. 203779s, WERBER et al. 'Preliminary purification of two human blood cell hormones by hydrophobic interaction chromatography.' Affinity Chromatogr. Biol. Recognit., [Proc. Int. Symp.], 5th. 1983, 495-497.	1-12 ----- 13-16																								
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																										
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td></td> </tr> <tr> <td>*B</td> <td>earlier document published on or after the international filing date</td> <td>*X</td> </tr> <tr> <td>*L</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*O</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>*Y</td> </tr> <tr> <td>*P</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td></td> <td></td> <td>*A</td> </tr> <tr> <td></td> <td></td> <td>document member of the same patent family</td> </tr> </table>			* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A	document defining the general state of the art which is not considered to be of particular relevance		*B	earlier document published on or after the international filing date	*X	*L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*O	document referring to an oral disclosure, use, exhibition or other means	*Y	*P	document published prior to the international filing date but later than the priority date claimed	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art			*A			document member of the same patent family
* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																								
*A	document defining the general state of the art which is not considered to be of particular relevance																									
*B	earlier document published on or after the international filing date	*X																								
*L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																								
*O	document referring to an oral disclosure, use, exhibition or other means	*Y																								
*P	document published prior to the international filing date but later than the priority date claimed	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																								
		*A																								
		document member of the same patent family																								
Date of the actual completion of the international search 23 FEBRUARY 2000		Date of mailing of the international search report 07 MAR 2000																								
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer  ANISH GUPTA Telephone No. (703) 308-0196																								

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/26241

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y - X	Chem. abstr. Vol. 126, No. 5, 03 February 1997 (Columbus, OH, USA), page 315, column 2, the abstract No. 57095j, BURG et al. 'Human erthropoietin recombinant production by fermentation and protein purification using a series of chromatographic steps.' PCT Int. Appl. WO 96 35, 718. 14 November 1996.	1-2 ----- 13-16